Health
China Sinopharm’s potential COVID-19 vaccine triggers antibodies in clinical trials: Journal – CGTN
The potential vaccine appeared to be safe and can trigger an immune response.
A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
The candidate has already moved into a late-stage trial, one of a handful of candidates being tested on several thousand people to see if they are effective enough to win regulatory approval.
Sinopharm is testing the potential vaccine in the United Arab Emirates in a Phase 3 tria…
-
Business22 hours agoThis ASX All Ords stock has more than doubled investor’s money since January. Here’s why it’s tipped to surge another 45%!
-
Business20 hours agoBroker names 2 small cap ASX shares to buy for big returns
-
Noosa News19 hours agoMin Woo Lee, Adam Scott and Cameron Smith in the mix after Australian PGA opening round in Brisbane
-
Business19 hours agoThese top ASX 200 stocks could rise 25% to 60%